Resultados: 217

    Diagnosis and management of heparin-induced thrombocytopenia: third edition

    Br. j. haematol; 204 (2), 2024
    This guideline updates and widens the scope of the previ-ous British Society for Haematology (BSH) Clinical guide-lines for Diagnosis and Management of Heparin-Induced Thrombocytopenia: Second Edition1 to include functional assays in the diagnosis of heparin-induced thrombocy...

    Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline

    This guideline provides evidence-based recommendations on appropriate indications and techniques for partial breast irradiation (PBI) for patients with early-stage invasive breast cancer and ductal carcinoma in situ. ASTRO convened a task force to address 4 key questions focused on the appropriate indic...

    The management of myelofibrosis: a British Society for Haematology guideline

    Br. j. haematol; 204 (1), 2024
    This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015 These guidelines aim to pro-vide healthcare professionals with clear guidance on stratified management for primary myelofibrosis (PMF)...

    Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology guideline

    Br. j. haematol; 204 (1), 2024
    The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with marginal zone lymphoma (MZL)....

    Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology guideline

    Br. j. haematol; 204 (1), 2024
    This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary m...

    AGA clinical practice guideline on the role of biomarkers for the management of Crohn’s Disease

    Gastroenterology; 6 (165), 2023
    Biomarkers are used frequently for evaluation and monitoring of patients with Crohn’s disease (CD). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the management of CD. A multidisciplinary panel of content ...

    Management of premenstrual Disorders ACOG clinical practice guideline nº 7

    Obstet. gynecol; 142 (6), 2023
    To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysi...

    CDC recommendations for hepatitis C testing among perinatally exposed infants and children: United States, 2023

    MMWR recomm. rep; 72 (4), 2023
    The elimination of hepatitis C is a national priority (https://www.hhs.gov/sites/default/files/Viral-Hepatitis-NationalStrategic-Plan-2021-2025.pdf). During 2010–2021, hepatitis C virus (HCV) acute and chronic infections (hereinafter referred to as HCV infections) increased in the United States, conseq...

    AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review

    Gastroenterology; 165 (5), 2023
    Exocrine pancreatic insufficiency (EPI) is a disorder caused by the failure of the pancreas to deliver a minimum/ threshold level of specific pancreatic digestive enzymes to the intestine, leading to the maldigestion of nutrients and macronutrients, resulting in their variable deficiencies. EPI is freque...

    A British Society for haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies

    Br. j. haematol; 203 (4), 2023
    The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement-mediated haemolytic uraemic syndrome (CM HUS); these ar...